In the immunotherapy against solid tumors, an anti-HER2 bispecific and biparatopic antibody zanidatamab exerted more potent CDC against HER2-positive breast cancers compared with clinically approved anti-HER2 mAb trastuzumab [48]. This evidence concerns the gene ERBB2 and breast carcinoma.